NasdaqGS:GOSSBiotechs
Assessing Gossamer Bio (GOSS) Valuation After FDA Progress and Pulmonary Hypertension Pipeline Advances
Gossamer Bio (GOSS) has caught the market’s eye this month, and for good reason. The company’s shares have been trading higher in response to encouraging FDA designations for its experimental drug seralutinib, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Along with a strong presence at recent investor conferences, Gossamer Bio appears determined to cement its position in these specialized lung disease markets...